Inmune Bio, Inc 8-K, filed Oct 19, 2022
Inmune Bio, Inc. (INMB)
About this 8-K
Inmune Bio, Inc filed this 8-K on October 19, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in charter) |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer | ||
| of incorporation) | Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On October 19, 2022, INmune Bio Inc. issued a press release announcing positive solid tumor data in multiple cancer lines resistant to NK killing that can be overcome with administration of INKmune. A copy of the press release is attached herewith as Exhibit 99.1.
The Company is filing as Exhibit 99.2 to this Current Report on Form 8-K a slide deck that the Company intends to use in a presentation.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
| 99.1 | Press Release dated October 19, 2022 | |
| 99.2 | Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMUNE BIO INC. | ||
| Date: October 19, 2022 | By: | /s/ David Moss |
| David Moss | ||
| Chief Financial Officer | ||
2
Exhibit 99.1

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
Dr. Mark Lowdell, CSO, Presented Latest Data in First Plenary Session at The Innate Killer Summit Europe, London Today
BOCA RATON, Fla, Oct. 19, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announces positive solid tumor data in multiple cancer lines resistant to NK killing that can be overcome with administration of INKmune.
Solid tumors represent 90% of adult human cancers while the majority of cell therapies focus on the 10% of cancers that are hematologic tumors, or “liquid tumors.” The current data provides insights into why the Company believes that INKmune arms Natural Killer (NK) to override immunosuppression and hypoxia in an active Tumor Microenvironment (TME) to kill solid tumors.
The interaction of the TME with cancer cells and immune cells can drive tumor progression and prevent many cell therapies from being effective. These complex interactions should be considered when designing cell therapies to treat solid tumors. In solid tumors, the TME is hostile to cell therapies because of (i) the presence of immunosuppressive immunoregulatory cells, and (ii) the low levels of oxygen (hypoxia). A cell therapy must operate in this hostile environment to successfully treat solid tumors,
INKmune converts patient’s normal resting NK (rNK) cells into potent memory-like NK cells that target solid tumors directly, even in the presence of immunosuppressive immunoregulatory cells and hypoxia associated with the TME. The Company’s pre-clinical data show that INKmune primes NK cells from patients and from healthy donors to lyse NK-resistant ovarian (CaOva), prostate (CaPros), renal (RCC) and nasopharyngeal (NPC) cancer cells. When compared to rNK cells, which are normal NK cells from healthy donors or patients before treatment with INKmune, the INKmune primed NK cells demonstrated enhanced ability to kill these resistant tumor cell lines.
The value in the tables is percent of tumor cells killed. For instance, in the table below looking at laboratory assay using healthy donor NK cells killing of a prostate cell line called DU145, resting NK cells that have not been primed with INKmune kill fewer than 4% of the DU145 cells in 4 hours. INKmune primed NK cells kill approximately 66% of DU145 cells in the same amount of time. Negative values mean that the tumor cells grew faster than the NK cells could kill them.
Healthy donor NK cell responses to NK-resistant tumor cell lines:
| Tumor Target |
% Tumor Cell Lysis (rNK) |
% Tumor Cell Lysis (INKmune -primed NK) |
Improvement | |||
| Prostate-DU145 | 3.87 | 66.17 | +++ | |||
| RCC-786O | -2.09 | 50.19 | +++ | |||
| RCC-ACHN | -5.03 | 34.75 | +++ | |||
| CaOva-SKOV3 | 12.32 | 28.50 | ++ | |||
| NPC-H3 | 6.61 | 45.86 | +++ | |||
| NPC-C17 | 0.50 | 31.04 | +++ |
Cancer patient NK cell responses to NK-resistant tumor cell lines:
| Patient ID | Tumor target |
% Tumor Cell Lysis (rNK) |
% Tumor Cell Lysis (INKmune -primed NK) |
Improvement | ||||
| CaOva1 | SKOV3 | 7.00 | 43 | +++ | ||||
| CaOva2 | SKOV3 | 4.00 | 50 | +++ | ||||
| CaOva3 | SKOV3 | 8.00 | 64 | +++ | ||||
| RCC1 | 768O | 36.40 | 32.3 | - | ||||
| RCC2 | 768O | 10.20 | 21 | + | ||||
| RCC3 | 768O | 20.70 | 19.6 | - | ||||
| RCC4 | 768O | 0.00 | 40 | +++ | ||||
| RCC5 | 768O | 19.80 | 47 | + | ||||
| RCC6 | 768O | 20.30 | 50 | + | ||||
| RCC7 | 768O | 16.90 | 54.4 | ++ | ||||
| RCC8 | 768O | 50.00 | 64.4 | + | ||||
| RCC9 | 768O | 14.20 | 32.7 | + |
The Company identified more than1,500 proteins that are upregulated in NK cells following INKmune priming and subsequent analysis compared them to NK cells primed with a cytokine cocktail of IL-12, IL-15 and IL-18. Of the 250 most upregulated proteins, 141 are completely unique to INKmune priming and are not upregulated by the cytokines IL-12, IL-15 and IL-18. Many of these unique proteins are involved in cell survival and the enhanced metabolism likely to protect INKmune primed NK cells in the TME. “We believe the upregulation of key proteins associated with enhanced metabolic fitness and mitochondrial repair in the NK cells are critical for NK survival in the TME of solid tumors,” said Dr. Mark Lowdell, the Company’s CSO.
There remains an unmet need for novel treatments in prostate, renal and nasopharyngeal cancers. The number of patients who could benefit exceeds 4 million annually in the US alone. These data support INmune Bio’s decision to transition INKmune trials into the treatment of solid tumors.
The company presented the data at the Innate Killer Summit Europe on October 19th. A video of the presentation will be uploaded to the company’s website by Wednesday next week.
About INKmune™
INKmune™ is a proprietary pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals akin to treatment with at least three cytokines in combination. INKmune™ is stable at -80oC and is delivered by a simple IV infusion. The INKmune:NK interaction ligates multiple activating and co-stimulatory molecules on the NK cell and enhances its avidity of binding to tumor cells; notably those resistant to normal NK-mediated lysis. Tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma, ovarian cancer, breast cancer and the solid tumors shown above.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
2
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
DMoss@INmuneBio.com
Investor Contact:
Jason Nelson
Core IR
(516) 842-9614 x-823
3
Exhibit 99.2

Arming NK ce l l s to ov e rride immunos u ppre s sio n i n the TME Professor Mark Lowdell CSO INmune Bio Inc.

This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward - looking statements. Such statements, include, but are not limited to, statements contained in this presentation relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward - looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward – looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward - looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward - looking statements. Important factors that could cause actual results to differ materially from those in the forward - looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors (including the risks contained in the section of this prospectus entitled “Risk Factors”) relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements . INB 03 and XPro 1595 are still in clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved . Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward - looking statements to conform these statements to actual results . INmune Bio Forward Looking Statement

Raji Lysis Raji Lysis

A B C C tr l D a y 1 C tr l D a y 7 TIML - N K ce ll s / NB1 6 Day 7 TIML - N K ce ll s / NA LM 1 6 Day 7 D E CellTrace TM Violet Fluorescence Cel l C o u n t 0 20 40 60 80 100 % specific lysis of K562 0 20 40 60 80 100 % specific lysis of RAJI 0 2 4 6 NK cell expansion (fold change)

20.3% CD69+ 11.8% CD69+

140 120 100 80 60 40 20 0 N umbe r o f con t ac t s (absolute count) 0' 15' 30' 45' 60' 0 10 20 30 40 50 60 T im e (m i nutes ) % NK:NK cell conjugates 0 20 40 60 % NK cell expression r N K : r NK rNK:TIM A B C D MoA of tumor - priming = serial activation of rNK 0 2 0 4 0 6 0 r N K r N K + I L 1 5 [ 1 n g / m L ] r N K + T p N K ( 1 : 1 0 ) + I L 1 5 [ 1 n g / m L % r N K r e c e p t o r e x p r e s s i o n NK - Tumor TROGOCYTOSIS


60 40 20 0 80 100 % ex p r e s s i o n Activation markers r N K NK+INB16 NK+NA L M 1 6 8 0 6 0 4 0 2 0 0 100 % expression Ch em oki n e receptors M atu r at i o n markers Inhibitory markers Immune checkpoints Effect of whole tumour priming on phenotype

1 6 2 4 4 8 - 1 0 0 0 1 0 0 2 0 0 3 0 0 OCP - Ascites derived NK cells Effect of NK priming on hypoxia - induced impairment of NK lysis % c h a n g e f r o m no rm o x i a IL15 treated INKmune treated Tumor - priming of TINK enhances killing of NK - resistant SKOV - 3 6 16 24 48 0 10 20 30 40 50 60 80 70 90 1 0 0 OVCAR3 h+n OCP Time (h) Specific Cytolysis (%) OCP - Ascites rNK OC P - Asc i t e s+ T p N K OCP - Ascites rNK HYP OCP - Ascites+TpNK HYP 0 5 0 1 0 0 % of specific lysis TpNK lyse multiple solid tumor cell lines rNK T p N K

Effects of in h ib i tory cell s i n the TME Myeloid - derived suppressor cells K562 lysis 5:1:1 S p e c i fc i c y t ol ys i s 8 0 6 0 4 0 2 0 0 100 Treg Suppression of NK - mediated lysis 0 1 0 2 0 3 0 4 0 % CD107a+ N I L A l l o 1 A l l o 2 A u t o K562 lysis 5:1:1 0 2 0 4 0 6 0 8 0 100 rNK rNK:CD33 (IL - 6) Allo 1 rNK:CD33 (VEGF) Allo 1 rNK:CD33 (IL - 6) Allo 2 rNK:CD33 (VEGF) Allo 2 rNK:CD33 (IL - 6) Auto rNK:CD33 (VEGF) Auto rNK - 1% O2 rNK:CD33 (IL - 6) Auto - 1% O2 rNK:CD33 (VEGF) Auto - 1% O2 % of specific lysis 1% O 2

, IL1A, IL1 B , IL3 R A , B , M AFF , M IF, M YC, M B 9 , PS M E2, RG S1 4 , CC L8 , CC L2 0 , CC L F 1 , CSF2, CXC L 1 , CX A M 1, ID O 1, IF NG , IL NF S F 4 , T NF S F 10 0 , CC L 1 , CC L3 , C T N F R SF 9 , T N FS F 1 0 , T R AF D 1 , downre L G A LS 3 , MR C 1 , TY RO B P ( 92 ) TLR 4 Upregulated ATF 3 , CCL 3 , CCL 4 , CD 70 , CD 80 , CD 274 , CSF 2 , CXCL 10 , DUSP 2 , FAS, ICAM 1 , Upregulated ATF 3 , CCL 1 , CCL 3 , CCL 4 IFNG, IL 1 A, IL 1 B, IL 23 A, IRF 8 , MIF, MYC, NFKB 1 , NFKBIA, NFKBIZ, RIPK 2 , SOCS 1 , SOCS 3 , CXCL 3 , CXCL 8 , FAS, ICAM 1 , IFNG, IL 1 T N F, T N FAIP 3 , T N FS F 1 0 , T R AF 1 ( 28 ) M Y D 88 , N FK B 1 , N FK B IA, N FK B I Z , R IPK C X C R 2 ( 38 ) 1 209 J Exp Med. 1998 Dec 7;188(11):2067 - 74. Stat5b is essential for natural killer cell - mediated proliferation and cytolytic activity. Imada K 1 , Bloom ET , Nakajima H , Horvath - Arcidiacono JA , Udy GB , Davey HW , Leonard WJ . Immunology. 1996 Jun;88(2):289 - 93. CD27/CD70 interaction directly induces natural killer cell killing activity. Yang FC 1 , Agematsu K , Nakazawa T , Mori T , Ito S , Kobata T , Morimoto C , Komiyama A . U p str e a m regulator Genes affected in TpNK Genes affected in LAK TNF Upregulated BCL6 , BIRC5 , CD69, CD70 , CD80, CD83, CD274, CDKN1A, CLIC4, CREM, CXCL9, CXCL10 , CXCL11, DUSP2, DUSP6, EGR2, EGR3 , ERCC1, FAS, FGFR1 , FOSL1, FSCN1, GADD45B, GCH1, HIF1A, HIVEP1, HPRT1, ICAM1, ICOSLG, IDO1, IFNG, IL1A, IL1B, IL4R, IL23A, I R F8 , LI F, M AP2K3 , M A R CKS L 1 , M IF, M SH2 , M YC, N A M PT, N FATC1 , N FK B 1, NFKBIA, NFKBIZ, NR4A2 , PSMB8, PSME2, RGS1, RIPK2, SERPINB9, SERPINE1 , SOCS1, S O CS3, SQS T M 1, S T A T5 A , TAP1 , TAP B P , T N F, T N FAIP 3 , T N FA I I P N 8 , T B N F R 1 S F 6 9 , T N FSF 9 , TNFSF10, TRAF1, TRAF2, VEGFA , downregulated CCR1 , LGALS3, THBD (82) Upregulated CASP7 , CASP10, CCL1 , CCL3, CCL4, CCL20 , CCL22 , CCR7, CD38 , CD40 , CD40LG , C D 69, C D 80, C D 83, C D 274, C D KN1A, CE B P B , C LI C4, C R E M , CSF 1 , CSF2, CXC L 1 , CXC L 2 , CXC L 3 , CXCL5 , CXCL8 , CXCL9, CXCL11, CYTIP , DPP4 , ERCC1, FAS, FOSL1, FSCN1, GADD45B, GCH1, HIF1A, ISG15 , ITGB7 , LAMP3 , LDLR , LIF, LT CXCR4 MYD88 , NAMPT, NFKB1, NFKBIA, HIVEP1, HPRT1, ICAM1, IDO1, IFNG IL4R, IL6 , IL15 , IL18R1 , IL23A, IRF1 , IRF8 , N FK B I I L E, - N 2 FK B I Z , P LAUR , PS M B 8, PS , R IPK2, SE R PIN B 2 , SE R PIN B 9, S O CS1, SOCS3, SQSTM1, STAT1 , STAT5A, TAP1, TAPBP, TNF, TNFAIP8, TNFRSF1B , TNFRSF9, TNFSF10, TRAF1, TRAF2, downregulated CEBPA , CXCR2 , F11R, LGALS3 (99) 6 3 NFκB co mp l ex Upregu l a t ed ATF3, B C L2 , B I R C3, B I R C5 , CC L3 , CC L4 , CC L8 , CC N B 2 5 , C D 2 6 9 2 , C D 80, C D 83, CD274, CDKN1A, CREM, CSF2, CXCL9, CXCL10 , CXCL11, FAS, GADD45B, GCH1, HIVEP1, ICAM1, ICOSLG , IDO1, IFNG, IL1A, IL1B, IL23A, IRF4, LTA, MYC, NAMPT, NFKB1, NFKBIA, NFKBIZ, SERPINE1 , SOCS1, SOCS3, STAT5A, TAP1, TNF, TNFAIP3 , TNFRSF9, TNFSF10, T R AF1, T R AF2, d o w n re g u l a te d M S H2 ( 48) Upr e 2 g u 3 l a t 6 ed ATF3, B C L2 , B I R C3, CC L3 , CCL C X C R 2 2 2 , CC R 7 , C D 40 , C D 69, C D 80, C D 83, CD274 , C D KN1A, CE B P B , C R E M , CS C L 2 , CXC L 3 , CXC L 5 , CXC L 8 , CXC L9, CXCL11, FAS, GADD45B, GCH1, HIVEP1, IC 1A, IL1B, IL6 , IL15 , IL23A, IRF1 , IRF4, LTA, LTB , MYC, NAMPT, NFKB1, NFKBIA, NFKBIE , NFKBIZ, PSMB9 , SERPINB2 , SOCS1, SOC S3, S TAT5 A , TAP1, TAP2 , T NF , T NFRS F 9 , T , T R AF1, T R AF2 ( 61) BCL6 IL1B Upregulated ATF3, BCL2, BIRC3, BTG2, CASP10, CCL3, CCL4, CD69, CD80, CD83, CD274, CEBPG, CSF2, CXCL9, CXCL10 , CXCL11, FAS, FOSL1, GADD45B, GCH1, HIF1A, ICAM1, N FK B 1, N FK B IA, N FK B I Z , NR 4A2, PS M B 8, PS M E2, R IPK2, S100A 1 I 0 N , S E B R P I 1 N B 6 9, SE R PINE 1 , ICOSLG , IDO1, IFNG, IL1A, IL1B, IL23A, IL4I1, IRF4, LIF, LTA, MIF, MYC, NAMPT, NFIL3, SOCS1, SOCS2, SOCS3, STAT3, STAT5B , TNF, TNFAIP3 , TNFRSF9, TNFSF10, VEGFA , downreg u l a t ed TH B D ( 57) Upregu l a t ed ATF 3 , B C L 2 , B I R C 3 , B T G 2 , CASP 1 C L 4 , CC L 2 0 , CC L 2 2 , CC R 7 , C D 40 , CD 40 LG , CD 69 , CD 80 , CD 83 , CD 274 , CEBPB, CEBPG , CSF 1 , CSF 2 , CXCL 1 , CXCL 2 , CXCL 3 , CXCL 5 , CXCL 8 , CXCL 9 , CXCL 11 , CYTIP , DPP 4 , FAS, FOSL 1 , G 6 PD , GADD 45 B, GCH 1 , HIF 1 A, ICAM 1 , IDO 1 , IF N G I , L IL 1 - A 2 , IL 1 B , IL 3 R A , IL 4 I 1 , IL 6 , IL 15 , IL 18 R 1 , IL 23 A, I R F 1 , I R F 4 , IS G 15 , LDL R , L IF, L TA, M IF, MYC, NAMPT, NFIL 3 , NFKB 1 , NFKBIA, NFKBIZ, PSMB 8 , PSMB 9 , PSME 2 , RIPK 2 , SERPINB 2 , SERPINB 9 , SOCS 1 , SOCS 2 , SOCS 3 , STAT 1 , STAT 3 , STAT 5 A, TNF, TNFRSF 9 , TNFSF 10 ( 75 ) IFNG Blo o d. 2005 Upregu l a t ed ATF3, B ID, CASP1 0 , CC L3 , CC L4 , CC L8, C D 80 , C D 83, C D 3 2 7 6 4, 9 C D KN1A, C LI C4, CREM, CSF2, CXCL9, CXCL10, CXCL11, EGR2, EGR3, FAS, FLT1 , GCH1, HIF1A, ICAM1, ICOSLG , IDO1, IFNG, IL1A, IL1B, IL23A, IRF4, IRF8, JAK3, LIF, LTA, MAP2K1 , MARCKSL1 , M IF, N A M PT, N FK B 1, N FK B IA, N FK B I Z , PIM2, PS M B 8, PS M E2, R IPK2, S100A 1 0 , SE R PIN B 9, SERPINE1 , SOCS1, SOCS2, SOCS3, SQSTM1, STAT3, TAP1, TAPBP, TNF, TNFRSF9, T N FSF 10 , V E G FA , downre g u l a t ed C LE C5A, L G A LS3 , TY RO B P ( 62) Mar 15;105(6):2428 - 35. Epub 2004 Nov 9. Upr e 4 g u 9 l a t 5 ed ATF3, B ID, CASP7 , CASP1 0 , CC L3 , CC L4 , CC L8 , CC L20 , CC L22 , CC R 1,C D 38 , C D 40, C D 40L G , C D 80, C D 83, C D 274, C D KN1A, CE B P , C LI C4, C R E M , CSF 1 , CSF2, CXC L1 , CXC L2 , CXC L3, CXCL8, CXCL9, CXCL11, DPP4 , FAS, GCH1, HIF1A, ICAM1, IDO1, IFNG, IL15 , IL18R1 , IL1A, IL1B, IL23A, IL3RA , IL6, IRF1, IR4, IRF8, ISG15 , JAK3, LAG3 , LAMP3 , LIF, LTA, LTB , MAFF , MIF, MX1, MX2, MYD88, NAMPT, NFKB1, NFKBIA, NFKBIZ, PIM2, PSMB8, PSMB9 , PSME2, RIPK2, SERPINB9, SOCS1, SOCS2, SOCS3 , SQSTM1, STAT1 , STAT3, TAP1, TAP2 , TAPBP, TNF, TNFRSF1B , g u l a t ed C LE C5A, C LE C7 A , C X C R4 , F11 R , FC GR 2 B , KL R K1 , NK cells th media t ed ly Saudemont at are activated by CXCL10 can kill dormant tumor cell sis and can express B7 - H1 that stimulates T cells. A 1 , Jouy N , Hetuin D , Quesnel B . s that resist CTL - , CCL20 , CCR7 , CD38 , CD40 , CD80, CD274, CSF2, CXCL2 , A, IL1B, IL6 , IL15 , IL23A, IRF1 , IRF8, MIF, MX1 , MYC, 2, SOCS1, SOCS3, TNF, TNFSF10, TRAF1 downregulated

I N K M U N E I S A “ P S E U D O K I N E ” MOA - INKmune Œ activates critical genes and pathways for enhanced NK function / survival INB16 upregulates 522 genes distinct from IL2 – including CD70, CXCL10, Stat5 INB16 upregulates 1461 proteins distinct from IL15 – including TIMM29, USP20 Target cell lysis proteins INB16 upregulates the same proteins as IL15 Mitochondrial survival proteins INB16 upregulates significantly more than IL15

rNK LAK - 15 CIML - NK INKMUNE - NK TpNK proteomics Proteins significantly increased in TpNK cf CIML - NK

I N K M U N E E N H A N C E S N K M E T A B O L I S M & S U R V I V A L Rapid proliferation of NK cells ex - vivo leads to reduced mitochondrial fitness; decreased membrane potential and increased levels of mitochondrial reactive oxygen species (mtROS) Mitochondrial fitness has to be restored for the persistence of long - term NK cell function; this is achieved by mitophagy or the removal of damaged mitochondria • LARP1 (promoter of mitophagy) is upregulated by IL - 15 but not by INKmune • BNIP1 (promoter of mitochondrial fitness) is upregulated by INKmune but not by IL - 15 0 20 40 60 Relative OCR (pmoles/min) Basal Mitochondria Respirati 1 0 0 80 60 40 20 0 - 20 Relative OCR (pmoles/min) Maximal Mitochondria Respiration - 1 5 0 - 1 0 0 - 5 0 0 50 1 0 0 Relative OCR (pmoles/min) Spare respiratory capacity IL15 upregulated nutrient receptors = 1 SLC1A4 INKmune upregulated nutrient receptors = 37 SLC39A9, SLC30A9, SLC25A16, SLC1A5, SLC25A38, SLC2A1, SLC39A10, SLC5A3, SLC25A14, SLC16A3, SLC35B2, SLC27A4, SLC19A1, SLC25A33, SLC25A40, SLC37A4, SLC25A22, SLC37A4, SLC12A4, SLC6A6, SLC25A19, SLC16A3, SLC25A53, SLC17A5, SLC39A8, SLC29A1, SLC35A2, SLC7A6, SLC25A26, SLC30A1, SLC18B1, SLC6A6, SLC25A3, SLC25A53, SLC39A8, SLC9A6, SLC11A2, SLC35A2, SLC12A7, SLC25A29

INKmun e : a mult i - dimensional “ pseudokine ” rNK cells (green) added to resistant tumor cells INKmune primed NK cells added to resistant tumor cells Low force causes break of immune synapse and NK collect in clusters Increasing force fails to break immune synapse and NK remain bound to tumor cells TpNK lyse NK - resistant ovarian cancer cells IL15 primed NK NK - resistant ovarian cancer cells IL2 primed NK DO NOT lyse NK - resistant ovarian cancer cells 0 200 800 1000 0 2 0 4 0 6 0 8 0 100 400 600 rForce (pN) SK - OV - 3 (n=3) 5 min % NK Cells Bound r e s t i n g N K TpNK NK IL - 2 N K - I L - 1 5 High avidity predicts tumor killing Low avidity predicts lack of killing MoA #1 – INKmune increases avidity of NK cell binding to tumor cells Avidity of tumor cell binding by resting and primed NK cells 0 2 0 0 8 0 0 10 0 0 0 50 1 0 0 400 600 r Fo r c e [ p N ] % NK cells bound rNK 15min T i M L - N K 5 m i n T i M L - N K 1 0 m i n T i M L - N K 1 5 m i n Ci M L - N K 15 m i n 0 10 20 30 40 50 1 5 0 % NK Cells Bound (200pN)

16 I N K M U N E I S A “ P S E U D O K I N E ” MO A - I N K m un e Œ I n cr e a s es Avidity of N K Cell Bi ndi n g to Tu m or Cel l s 0.0 5.0 25 . 0 20 . 0 15 . 0 10 . 0 30 . 0 40 . 0 35 . 0 24 . 0 36 . 0 48 . 0 60.0 Time (hr Post - Treatment) 72 . 0 84 . 0 % Cytolysis rNK 20:1 TpNK 5:1 xCelligence in hypoxia Real - Time Cytolysis Plot NK added IN K mune added

A M U L T I - D I M E N S I O N A L “ P S E U D O K I N E ” MOA – INKmune Œ Differentiates Resting NK to “Memory - Like” NK Cells Cytokine cocktail (IL - 12/15/18) drives resting NK to memory - like NK ( S ci T ransl M e d 2016 ; Ro m ee ,F enhege r , e t al) 0 5000 10000 15000 NK G 2 C M e F I 0 10000 20000 30000 40000 NK G 2 D M e F I 0 10000 20000 30000 N KG2 A M e F I 0 20000 40000 60000 80000 CD9 4 M e F I 0 5000 10000 15000 20000 CD1 6 M e F I INKmune Generates Memory - like NK Cells equivalent to IL - 12, IL - 15 and IL - 18 17

INKmune infusions: D 1 7 th July D 8 14 th July D 15 21 st July All infusions well tolerated, no infusional AEs Episode of neutropenic sepsis ( Stenotrophomonas ) D29 BM 9% blasts RAD1 45% D100 BM 13% blasts RAD1 38% Las t f/u: Reduced transfusion requirements Fully active, regular exercise – ECOG 0 0 20 40 60 80 % Activated (CD69+) of total NK N K G2 D + NKp46+ C D 1 6 + 0 5 0 10 0 15 0 20 0 25 0 0 2 0 4 0 6 0 8 0 Concentration [pg/ml] Concentration [pg/ml] MIP - 1beta M I P - 1 a l ph a E o t a x i n TNF alpha 0 5 0 10 0 15 0 0 100 0 200 0 300 0 Concen t ra ti on [ pg / m l ] Concen t ra ti on [ pg / m l ] I L - 1 2 I L - 1 5 I L - 2 R I L - 8 D15 D43 D73 D119 D15 D43 D73 D119 6 0 4 0 2 0 0 8 0 100 In vitro Tumor Killing assay % s p ec i f i c l ys i s P B N K + K5 6 2 P B NK+R a j i 03/18 04/18 11/20 01/21 04/21 07/21 08/21 11/21 0 1 0 2 0 3 0 4 0 5 0 Laurel Subject 03 Da t e % R A D 1 c tDN A B l a s t s I N K m u n e x 3 Azac i t i dene x19 T u m o r - p r i m i n g i n v i v o MOA – IN K mune Œ gene r ates “Memo ry - Like” NK Ce l ls Patient 1 (trial #3) Trial entry April 2021 BM 17% blasts – ECOG 2

0 5 0 10 0 15 0 20 0 25 0 0 2 0 4 0 6 0 8 0 Concen t ra ti on [ pg / m l ] Concen t ra ti on [ pg / m l ] M I P - 1 be t a M I P - 1 a l ph a E o t a x i n TNF alpha 0 5 0 10 0 15 0 0 100 0 200 0 300 0 Concen t ra ti on [ pg / m l ] Concen t ra ti on [ pg / m l ] I L - 1 2 I L - 1 5 I L - 2 R IL - 8

C o n c l u s i o n s • NK interaction with some tumor cells provides priming signals which drive a type of ml - NK cell - TpNK • TpNK target hematological and solid tumors and can be generated from patient NK cells • TpNK are not inhibited by self MHC – akin to CIML - NK • TpNK show increased activity in extreme hypoxia and in presence of MDSC and Treg • TpNK proteome includes • Mitochondrial survival proteins • Nutrient receptors • Diapedesis - associated proteins • Cytokine secretion associated proteins • Lytic pathway associated proteins • Cell proliferation associated proteins • TpNK show enhanced metabolic profile comparable to CIML - ML but with resilience of spare capacity • In vivo administration of INKmune is safe and induces ml - NK in vivo , with systemic cytokine secretion akin to in vitro data and long term persistence of activated NK cells in vivo in 3 of 4 patients treated.

Acknowledgements Janet North Dr Ismail Bakhsh Dr May Sabry Dr Xenia Charalambous Aga Zubiak Helena Arellano Ballestero Dr Ben Weil Dr Rita Rego Carla Carvalho Simon Hood Prof Graham Pockley Dr Panagiotis Kottaridis Dr Maria Tsirogianni Dr Kim Orchard Dr Chris Dalley Dr Debbie Richardson Das Kushal Dr Dimitra Peppa Prof Maxine Tran